Latigo BiotherapeuticsLTGO
Recorded

Latigo Biotherapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration28 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Akash TewariJefferies pharma and biotech research lead; conference host

Alrighty. Good afternoon, everyone. Day one of our Jefferies London Healthcare Conference. It really has been a joy to see all the clients and all the companies. My name's Akash Tewari. I lead our pharma and biotech research efforts here at the firm. I have the pleasure of hosting Latigo, not Latigo. I've made this mistake. Todd and Neha, it's really great to host you. Todd, why don't I hand it off to you for some intro remarks, and we'll get started.

ToddCEO

Awesome. Thanks, Akash. Hey, good afternoon, everybody, as well. Thanks for being here. Excited to be here. I've been in my job about two weeks. I come with a background deep in commercial, probably 30-plus years in the industry, the majority of that around pain, over 15 pain drugs that I've either launched or managed. I got a number of products approved, built a number of companies. A lot of commercialization deep as we think about the next step for Latigo. We've done a tremendous job with clinical progression. The IPO was a phenomenal success. Now the next step is really building out the commercial team to match the current team we have and prepare with the data that we are initially seeing that looks differentiated and really gives us kind of optimism on what we could do in the marketplace.

ToddCEO

The earlier we get involved, the more we can start to influence particularly the payers, maybe the medical side and policy. That gives us a lot of opportunity to kind of highlight and discuss our differentiation to get improvement in that. We're pretty excited about where Latigo is. We obviously have the abdominoplasty study has been completed, published in the New England Journal of Medicine. Next study will be our bunionectomy. We also have a safety study, which we're guiding to be read out second half of next year. We also have in the chronic OA, we have LTG-321, which is in process with its phase II proof of concept study that we also guide to read out second half of 2027. We have obviously further work being done.

ToddCEO

LTG-418 is a little bit deeper in our pipeline, but it's a next generation, we like to think of it, NaV1.8, that we can optimize and then further work in our discovery group, not only on 1.8 optimization, but kind of further targets that we're looking at. A lot of great progress, but also a lot of excitement for what we can do with both onzotrigine when it eventually will get approved, and then also the rest of the pipeline, which I think when you look at it, we're probably the broadest and deepest pipeline as we build out that best-in-class innovative pain company that we're working on.

Akash TewariJefferies pharma and biotech research lead; conference host

Understood. Todd, I am going to ask you the question you probably get in every single one of these meetings, which is, it is not typical to have a management change, and I think we all have a lot of respect for Nima. Why now? From a board perspective, why did the change make sense at this time point? You have a ton of experience when you think about pain launches and commercial launches. When you are really building out a market like NaV1.8, I mean, A, how do you see the market fundamentally differently than Vertex, and why do you need to start doing some of that work now?

ToddCEO

Yeah. No, fair. Probably three questions in there. Probably just first, and we have answered this, and the good news is I think everybody sees, even though the transition from Nima to myself may be a little bit abrupt, but very smooth, right? I think I have the deep pain experience and commercialization, which is that next phase we are moving into. Fortunate enough to have Nima, who built out a great team, led the team through the outsized IPO. He is able to stay on as an advisor through 2027. So, a lot of continuity. We have a great team in place. There will be no changes. I have been fortunate enough to be able to work with a team that, from top to bottom, seems to be top in the game, which is great.

ToddCEO

What you will see us maybe adding a few people in the commercial space, some commercial leadership will be coming in soon. Really just opportunistic. I sold a company, Corium, which was in the ADHD space, to Collegium. That wrapped up really at the end of the summer, as I was looking at a number of other things and as we are looking at Latigo really moving into this commercial space. If I took something else, I would be out of circulation for three to five years. So, a little bit opportunistically, the board decided let us make the move then now to commercialization, which really leads to the next question, which is when should we be doing something? Really today, right? We have really good data that has been published. First of all, unique that it got published.

ToddCEO

I think also the differentiation that it showed in onset, with 52 minutes versus JOURNAVX, 119 minutes, two and a half times faster. As all of us know in the marketplace, the behavior is shifted for no other reason than onset, right? Doctors need to know that it is going to work fast, work for patients. On a lot of levels, that is important to them. It is really, for the majority of doctors, unless you are an academic, it is really the only thing that is going to matter to them.

ToddCEO

With that puts us in a position where today, and we have already even in the last couple weeks have had a number of advisory meetings that we are working on, to really start forming how do we position ourselves because of the differentiation we have, because of how large the market is, and as you look at JOURNAVX and what it has done, right? I think it is a tale of two cities. A lot of people would say, "Hey, it is early launch. It was not really that great." What it has ended up in is really validating this NaV1.8, that the market is hungry for an alternative to opioids or even NSAIDs. Its latest data that it shared two weeks ago showed over 2 million scripts run rate in both NRX and TRX, and a 50% growth in its volume quarter-over-quarter. That is two years in the launch.

ToddCEO

That is actually pretty significant. I think as you think about when we might come on the market for onzotrigine, that is going to be well past 2 million scripts. That could be 2.5, 3 times. No one is guiding to anything, but you can imagine how big that will be. When we look at then launching into a marketplace, a second to market, we get to learn a lot. Where we are going to be able to step into is when we can come to market, talk to doctors about a 53-minute onset versus 119 minutes. When you think about why they want to move away from the opioids and NSAIDs, what they really want is something safer, they want something cleaner. Though JOURNAVX is relatively clean compared to those, it does have drug-drug interactions. We are not seeing those in our preclinical or even in the current data.

ToddCEO

Now we can walk in and tell a doctor that has already adopted 1.8 as an acute pain drug. Doctor, we have a more efficacious product, and we are a little bit cleaner, so why not move your business to that? On top of that, there are doctors sitting on the sidelines right now that really want something different, but they do not feel like they are getting the efficacy out of it. We can now pull in and really expand the market to that point. So we have a nice chance to kind of cannibalize what is out there, which is a great fast start for anybody. Secondly, we can expand the market. The second piece to how we have to look at it and why we need to start today is really it is the economics around it, right? It is the gross-to-net. Everybody now knows the number one strategic lever in commercialization is gross-to-net.

ToddCEO

It is the profitability per script. When you look at what JOURNAVX did, in this last quarter, they ended up at about a 76%-78% gross-to-net. That is an anomaly, right? They had a transfer from one of their government contracts. What they are going to settle into is about 50%-60%. I got to be honest, I think if most of us want to look, novel first to market differentiated products, that is a high mark. I think that speaks to their efficacy, right? Also the label that they really came to market with.

ToddCEO

We're going to get to come with not only the efficacy we talked about, we're also working, as you think about the two studies we have, both with opioid sparing as we looked at the rescue data. Then we're adding the Vicodin arm that we had in the abdominoplasty, and we're adding Percocet to the bunionectomy arm. That just gives us a fullness of label that as we start now interacting with the payers, we can start and really influencing the clinical and the policy kind of decision makers. If you don't do that now and you wait till six, nine months before launch, you're really just in that economic game, whereas now we have a chance to start to influence that. The other big piece we have is that policy's evolving.

ToddCEO

Right now, we know the NOPAIN Act really has an impact in the hospital. Because of that, we're going to get differential benefit from that. We also, because we have differentiation, we can get more aggressive in how we expand that. Then I think finally, just when you look at the programs, because we're second to market, we're not going to have to deal with all the patient support programs that they had to. Because we have differential efficacy, we're not going to have to keep them up. When you do that really gives you kind of now this profitability of script that we can look at being differentiated, but it also looks at the volume, could be really exciting for what we launch into.

Akash TewariJefferies pharma and biotech research lead; conference host

That's very helpful. I just want to put a finer point on that. Vertex absolutely has talked about long-term gross-to-net being that kind of 50%-60% range, which to be fair, I mean, it's pain, it's an in-hospital launch in some instances. That is not unusual. What you're saying, I think it's one of the first times I've heard your team say this. To be clear, if Vertex is saying gross-to-net is 50%-60%, what's your sense if you can get opioid sparing on the label, if you have a faster onset of effect? Are you saying you might have a material benefit on long-term gross-to-net versus what we see with JOURNAVX?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day